The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review

Abstract

The meeting of the expert council concerning the application of new highly selective inhibitor of Brutons tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma was held in Moscow on April 21, 2021. The leading Russian experts in the field of oncohematology took part in the meeting.

Keywords

• mantle cell lymphoma
• bruton’s tyrosine kinase inhibitor
• zanubrutinib